OBJECTIVE: Serum cancer antigen (CA) 125 is the only biomarker used frequently in women with or at risk for ovarian cancer. However, the same reference level is used before and after (prophylactic) bilateral salpingo-oophorectomy (BSO). We evaluated the effect of BSO on CA125 level in BRCA mutation carriers and tested which factors interact with the change in CA125 level. METHODS: All women who participated in the Nijmegen gynecological screening program and underwent prophylactic BSO were included. Information was obtained on age, smoking, menopausal state, previous hysterectomy and breast cancer, histopathological examination of the adnexa, hormone therapy use, and CA125 level before and after surgical operation. Ovarian volume was calculated. The logarithmic-transformed CA125 levels were used in a linear mixed model to study the relative change in CA125 level and possible interaction. RESULTS: In 60 women, a relative decrease of 18% in CA125 level after BSO was found (P < 0.01). The median serum CA125 level was 10.15 U/mL before and 8.36 U/mL after BSO. Menopausal state interacted with CA125 before and after the surgical operation (P < 0.01). In addition, ovarian volume did not explain the difference in CA125 level (P = 0.94). CONCLUSIONS: BRCA mutation carriers show a relative decrease in CA125 level after BSO. Menopausal state interacts with CA125. Ovarian volume was excluded as a confounder. Possibly, the hormonal effect of ovaries plays a role in the CA125 level. Our study suggests that not the reference level of 35 U/mL but a lower level, as already suggested for postmenopausal women, should be applied to women after a salpingo-oophorectomy.
OBJECTIVE: Serum cancer antigen (CA) 125 is the only biomarker used frequently in women with or at risk for ovarian cancer. However, the same reference level is used before and after (prophylactic) bilateral salpingo-oophorectomy (BSO). We evaluated the effect of BSO on CA125 level in BRCA mutation carriers and tested which factors interact with the change in CA125 level. METHODS: All women who participated in the Nijmegen gynecological screening program and underwent prophylactic BSO were included. Information was obtained on age, smoking, menopausal state, previous hysterectomy and breast cancer, histopathological examination of the adnexa, hormone therapy use, and CA125 level before and after surgical operation. Ovarian volume was calculated. The logarithmic-transformed CA125 levels were used in a linear mixed model to study the relative change in CA125 level and possible interaction. RESULTS: In 60 women, a relative decrease of 18% in CA125 level after BSO was found (P < 0.01). The median serum CA125 level was 10.15 U/mL before and 8.36 U/mL after BSO. Menopausal state interacted with CA125 before and after the surgical operation (P < 0.01). In addition, ovarian volume did not explain the difference in CA125 level (P = 0.94). CONCLUSIONS: BRCA mutation carriers show a relative decrease in CA125 level after BSO. Menopausal state interacts with CA125. Ovarian volume was excluded as a confounder. Possibly, the hormonal effect of ovaries plays a role in the CA125 level. Our study suggests that not the reference level of 35 U/mL but a lower level, as already suggested for postmenopausal women, should be applied to women after a salpingo-oophorectomy.
Authors: Ying Chen; Elizabeth Bancroft; Sue Ashley; Audrey Arden-Jones; Sarah Thomas; Susan Shanley; Sibel Saya; Emma Wakeling; Rosalind Eeles Journal: Fam Cancer Date: 2014-06 Impact factor: 2.375
Authors: Toshiya Abe; Chiho Koi; Shiro Kohi; Ki-Byung Song; Koji Tamura; Anne Macgregor-Das; Naoki Kitaoka; Miguel Chuidian; Madeline Ford; Mohamad Dbouk; Michael Borges; Jin He; Richard Burkhart; Christopher L Wolfgang; Alison P Klein; James R Eshleman; Ralph H Hruban; Marcia Irene Canto; Michael Goggins Journal: Clin Gastroenterol Hepatol Date: 2019-10-30 Impact factor: 11.382
Authors: Renée T Fortner; Allison F Vitonis; Helena Schock; Anika Hüsing; Theron Johnson; Raina N Fichorova; Titilayo Fashemi; Hidemi S Yamamoto; Anne Tjønneland; Louise Hansen; Kim Overvad; Marie-Christine Boutron-Ruault; Marina Kvaskoff; Gianluca Severi; Heiner Boeing; Antonia Trichopoulou; Vassiliki Benetou; Carlo La Vecchia; Domenico Palli; Sabina Sieri; Rosario Tumino; Giuseppe Matullo; Amalia Mattiello; N Charlotte Onland-Moret; Petra H Peeters; Elisabete Weiderpass; Inger Torhild Gram; Mie Jareid; J Ramón Quirós; Eric J Duell; Maria-Jose Sánchez; María Dolores Chirlaque; Eva Ardanaz; Nerea Larrañaga; Björn Nodin; Jenny Brändstedt; Annika Idahl; Kay-Tee Khaw; Naomi Allen; Marc Gunter; Mattias Johansson; Laure Dossus; Melissa A Merritt; Elio Riboli; Daniel W Cramer; Rudolf Kaaks; Kathryn L Terry Journal: J Ovarian Res Date: 2017-03-20 Impact factor: 4.234